NSISBC.XD DXE
Novonesis (Novozymes) B
1W: -1.6%
1M: -7.6%
3M: -2.5%
YTD: +7.9%
1Y: -0.6%
kr 422.00 ($63.27)
+4.60 (+1.10%)
Weekly Expected Move ±3.1%
kr 391
kr 404
kr 417
kr 431
kr 444
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$28.6B
+59.7% ▲
5Y CAGR: +14.7%
Gross Profit
$14.9B
+52.9% ▲
5Y CAGR: +13.2%
Operating Income
$3.7B
-6.0% ▼
5Y CAGR: +0.8%
Net Income
$2.3B
-24.6% ▼
5Y CAGR: -6.3%
EPS (Diluted)
$8.21
-24.5% ▼
5Y CAGR: -5.7%
EBITDA
$8.1B
+43.3% ▲
5Y CAGR: +12.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $14.0B | $15.0B | $17.6B | $17.9B | $28.6B |
| YoY Growth | -2.5% | +6.7% | +17.4% | +2.0% | +59.7% |
| Cost of Revenue | $6.2B | $6.3B | $8.0B | $8.2B | $13.7B |
| Gross Profit | $7.9B | $8.6B | $9.6B | $9.7B | $14.9B |
| Gross Margin | 56.0% | 57.8% | 54.6% | 54.3% | 52.0% |
| R&D Expenses | $1.9B | $2.0B | $2.0B | $2.0B | $3.1B |
| SG&A Expenses | $2.3B | $2.8B | $3.2B | $3.3B | $5.7B |
| Operating Expenses | $4.2B | $4.6B | $5.0B | $5.7B | $11.1B |
| Operating Income | $3.7B | $4.0B | $4.6B | $4.0B | $3.7B |
| Operating Margin | 26.1% | 26.8% | 26.0% | 22.2% | 13.1% |
| Interest Expense | $0 | $0 | $0 | $0 | $600M |
| Income Before Tax | $3.5B | $3.9B | $4.6B | $3.9B | $3.1B |
| Tax Expense | $695M | $779M | $870M | $870M | $830M |
| Net Income | $2.8B | $3.1B | $3.7B | $3.0B | $2.3B |
| Net Margin | 20.2% | 21.0% | 20.9% | 16.9% | 8.0% |
| EPS (Diluted) | $10.02 | $11.23 | $13.19 | $10.88 | $8.21 |
| EBITDA | $4.7B | $5.1B | $5.7B | $5.6B | $8.1B |
| Shares Outstanding | 282M | 280M | 279M | 278M | 278M |